Mercado cerrado -
Otros sitios de cotización
|
Después de cerrar 01:32:10 | |||
9,19 USD | -5,94 % | 9,17 | -0,22 % |
07/05 | Las acciones de Neumora Therapeutics caen al reducirse las pérdidas del 1T | MT |
07/05 | Neumora Therapeutics, Inc. Resultados del primer trimestre finalizado el 31 de marzo de 2024 | CI |
Resumen de negocios
Número de empleados: 120
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Carol Suh
FOU | Founder | 33 | 01/11/19 |
Henry Gosebruch
CEO | Chief Executive Officer | 51 | 18/07/23 |
Paul Berns
FOU | Founder | 57 | 01/11/19 |
Joshua Pinto
DFI | Director of Finance/CFO | 38 | 01/06/21 |
Raj Manchanda
CTO | Chief Tech/Sci/R&D Officer | 58 | 01/07/23 |
Nicholas Brandon
CTO | Chief Tech/Sci/R&D Officer | 50 | 01/04/20 |
Robert Lenz
CTO | Chief Tech/Sci/R&D Officer | - | 10/10/23 |
Corporate Officer/Principal | 48 | 01/08/21 | |
Amy Sullivan
HRO | Human Resources Officer | - | 01/01/21 |
Lori Houle
PRN | Corporate Officer/Principal | 57 | 01/04/21 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Paul Berns
FOU | Founder | 57 | 01/11/19 |
May Kin Ho
BRD | Director/Board Member | 71 | 01/04/21 |
Kristina Burow
BRD | Director/Board Member | 50 | 01/01/20 |
Matthew Fust
BRD | Director/Board Member | 59 | 01/12/20 |
Henry Gosebruch
CEO | Chief Executive Officer | 51 | 18/07/23 |
Alaa Halawa
BRD | Director/Board Member | 42 | 01/09/21 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 159 523 997 | 114 661 077 ( 71,88 %) | 0 | 71,88 % |
Información de la empresa
Sector
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
-46,10 % | 1466,03 M | |
+17,96 % | 44,96 mil M | |
+1,17 % | 42,65 mil M | |
+48,77 % | 41,85 mil M | |
-4,27 % | 29,04 mil M | |
+11,42 % | 26,08 mil M | |
-21,39 % | 19,03 mil M | |
+4,86 % | 12,75 mil M | |
+27,29 % | 12,06 mil M | |
-3,50 % | 11,75 mil M |
- Bolsa de valores
- Acciones
- Acción NMRA
- Empresa Neumora Therapeutics, Inc.